TY - JOUR
T1 - Management of immunotherapy-related toxicities, version 1.2020 featured updates to the NCCN guidelines
AU - Thompson, John A.
AU - Schneider, Bryan J.
AU - Brahmer, Julie
AU - Andrews, Stephanie
AU - Armand, Philippe
AU - Bhatia, Shailender
AU - Budde, Lihua E.
AU - Costa, Luciano
AU - Davies, Marianne
AU - Dunnington, David
AU - Ernstoff, Marc S.
AU - Frigault, Matthew
AU - Kaffenberger, Benjamin H.
AU - Lunning, Matthew
AU - McGettigan, Suzanne
AU - McPherson, Jordan
AU - Mohindra, Nisha A.
AU - Naidoo, Jarushka
AU - Olszanski, Anthony J.
AU - Oluwole, Olalekan
AU - Patel, Sandip P.
AU - Pennell, Nathan
AU - Reddy, Sunil
AU - Ryder, Mabel
AU - Santomasso, Bianca
AU - Shofer, Scott
AU - Sosman, Jeffrey A.
AU - Wang, Yinghong
AU - Weight, Ryan M.
AU - Johnson-Chilla, Alyse
AU - Zuccarino-Catania, Griselda
AU - Engh, Anita
N1 - Publisher Copyright:
© JNCCN—Journal of the National Comprehensive Cancer Network
PY - 2020
Y1 - 2020
N2 - The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.
AB - The NCCN Guidelines for Management of Immunotherapy-Related Toxicities provide interdisciplinary guidance on the management of immune-related adverse events (irAEs) resulting from cancer immunotherapy. These NCCN Guidelines Insights describe symptoms that may be caused by an irAE and should trigger further investigation, and summarize the NCCN Management of Immunotherapy-Related Toxicities Panel discussions for the 2020 update to the guidelines regarding immune checkpoint inhibitor–related diarrhea/colitis and cardiovascular irAEs.
KW - Antineoplastic Agents, Immunological/adverse effects
KW - Humans
KW - Immunotherapy/methods
KW - Neoplasms/drug therapy
UR - http://www.scopus.com/inward/record.url?scp=85081374182&partnerID=8YFLogxK
UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=purepublist2023&SrcAuth=WosAPI&KeyUT=WOS:000519548500003&DestLinkType=FullRecord&DestApp=WOS
U2 - 10.6004/jnccn.2020.0012
DO - 10.6004/jnccn.2020.0012
M3 - Article
C2 - 32135517
SN - 1540-1405
VL - 18
SP - 230
EP - 241
JO - Journal of the National Comprehensive Cancer Network : JNCCN
JF - Journal of the National Comprehensive Cancer Network : JNCCN
IS - 3
ER -